►
From YouTube: Keynote Panel: Fighting Fraud and Error in Vaccine Supply Chains - Antares Vision, Merck, Zuellig
Description
Keynote Panel: Fighting Fraud and Error in Vaccine Supply Chains - Paolo Migliari, Merck Sharp & Dohme; Lidija Pozaic Frketic, Antares Vision Group; Daniel Laverick, Zuellig Pharma; Brian Behlendorf, Hyperledger
To learn more about Hyperledger, the open source community focused on developing a suite of stable frameworks, tools and libraries for enterprise-grade blockchain deployments. Which serves as a neutral home for various distributed ledger frameworks including Hyperledger Fabric, Sawtooth, Indy, as well as tools like Hyperledger Caliper and libraries like Hyperledger Ursa click here: https://www.hyperledger.org/
Session Details & Slides (if available)- https://sched.co/j4HY
Access All Sessions: https://events.linuxfoundation.org/hyperledger-global-forum/program/schedule/
----
Hyperledger – Open Source Blockchain Technologies
Hyperledger is an open source community focused on developing a suite of stable frameworks, tools and libraries for enterprise-grade blockchain deployments.
It serves as a neutral home for various distributed ledger frameworks including Hyperledger Besu, Fabric, Sawtooth, Indy, as well as tools like Hyperledger Avalon, Cactus and libraries like Hyperledger Aries, Ursa. Learn more about Hyperledger projects: https://www.hyperledger.org/use
Case Studies: https://www.hyperledger.org/learn/case-studies
Training & Certification: https://www.hyperledger.org/learn/training
Tutorials: https://www.hyperledger.org/use/tutorials
Webinars: https://www.hyperledger.org/learn/webinars
Events: https://www.hyperledger.org/events
Vendor Directory: https://www.hyperledger.org/use/vendor-directory
Subscribe to the Hyperledger Newsletter: https://www.hyperledger.org/newsletter
Follow-us on Twitter @Hyperledger
Learn about Hyperledger Membership: https://www.hyperledger.org/about/join
#Hyperledger #HyperledgerGlobalForum2021 #Blockchain
A
So
let
me
start
out
by
making
some
introductions
with
us
is
paolo,
apollo,
migliari
who's,
the
connected
channel
lead
for
merck,
sharp
and
doma
daniel
lavrick,
who
is
head
of
sap,
and
it
solutions
for
zulig,
pharmaceutical
and
lydia
prozac
who's,
the
business
development
manager
for
pharma
and
smart
digital
innovation
with
antares
vision,
group
and
managing
director
of
trade
ticity.
So,
thank
you
all
three
of
you
for
joining
us.
A
I
really
I
wanted
to
make
sure
that
we
had
a
chance
to
talk
about
one
of
the
most
important
applications
of
blockchain
technology,
which
is
not
just
supply
chains,
but
supply
chain.
Specifically
in
the
pharmaceutical
sector.
I
mean
we've
heard
about
use
of
supply
chains
during
this
pandemic
for
ppe
supplies,
for
sharing
data
sets
and
those
sorts
of
things
and
vaccine
passports.
A
But
many
of
these
vaccines
need
to
be
stored
continuously
at
very
cold
temperatures,
which
will
not
be
easy
to
do,
and
the
support
for
and
the
opportunity
for
fraudulent
vaccines
to
enter
the
market
seems
vast
with
so
many
different
government
and
non-government
actors
participating
in
this
chain.
So
really
what
I
want
to
explore
with
this
panel
is,
can
distributed,
ledger,
be
effective
in
helping
us
track,
trace
and
ensure
the
safety
of
the
global
vaccine
supply
chain.
And
how
quickly
can
we
deploy
this?
Is
it
being
deployed
now?
A
What
are
what
are
the
benefits,
or
is
this
just
a
hammer
trying
to
find
a
nail?
So
with
that?
Let
me
take
a
breath
and
ask
each
of
our
panelists
to
take
a
few
minutes
to
introduce
themselves
and
talk
about
what
their
organizations
have
been
doing
in
this
space.
So
why
don't?
I
start
actually
with
lydia.
B
Okay,
hello,
everyone
good
morning,
good
afternoon,
good
evening,
I'm
really
happy
to
be
here
in
front
of
antares
vision
and
brian.
We
really
want
a
lot
of
eggs
and
a
lot
of
chicks
and
we
even
want
a
friends
of
ducks
and
turkeys.
So
that's
why
we're
here
and
that's
why
we
participate
in
all
the
initiatives,
because
we
do
believe
in
a
in
a
blockchain.
B
So
on
that
behalf,
we
cover
really
end-to-end
track
and
trace
by
all
means
from
the
machines
to
of
the
production
to
the
software
solutions.
So
there
you
go,
we
we
have
a
lot
to
say
regarding
the
the
protection
of
the
products,
in
particular
in
pharmaceutical
environment,
primarily
with
the
background
of
serialization.
However,
now
we
are
entering
blockchain
discussion,
so
I
mean
I
don't
want
to
go
any
further
at
this
moment,
but
will
be
more
chance
to
say
a
few
more
words.
A
C
At
this
moment
in
time,
and
we've
been
doubling
in
in
blockchain
for
for
really
more
around
about
three
three
and
a
half
years
working
very
closely
with
paulo
actually
on
some
projects
with
them
with
msd
and
what
we
we're
doing.
There
is
really
to
try
and
empower
patients
to
to
have
a
window
or
an
application
that
can
allow
them
to
verify
the
authenticity
of
a
joke
before
they
take
it.
It's
a
huge
problem
in
in
asia.
D
Yeah,
okay,
first
of
all,
hello
to
everybody,
I'm
paulo
miyari,
I'm
from
msd,
I
mean
my
msd
in
europe,
america,
as
in
in
usa.
Okay,
it's
it's
one
of
the
leading
pharmaceutical
company.
We
are
active
in
the
oncology
vaccine
infection,
disease,
carbon
18,
cardo
metabolic
disease
and
also
we
have
also
a
division
that
is
a
animal
health.
Okay,
I
would
say
that
we
are
quite
big.
We
are
really
global.
We
are
almost
70.
D
We
are
almost
74
000
employees,
but
the
most
important
thing
that
we
we
are
using
something
like
14
000
billion
research
in
development,
mainly
on
the
on
the
on
the
on
the
pharmacy,
and
also
we
have
something
like
three
billion
of
projects
in
in
in
really
in
philanthropic
approach.
Okay,
and
I
was
really
to
introduce
that
because
blockchain
is
becoming
one
of
the
main
topic
that
we
are
really
thinking
to
do
in
my
work,
we
we
I'm
leading
the
connected
channel,
so
the
idea
of
being
connected.
D
China
is
because
we
believe
that
first
of
all,
blockchain
is,
is
a
team
sport.
So
it
means
that
we
need
to
really
to
approach
always
maintaining
the
right
level
of
competition.
We
do
all
the
other
because
of
the
competition
is
one
that
is
the
most
important
okay.
We
believe
that
is
there
some
area
that
need
to
have
a
mature
collaboration,
especially
when
you
are
going
to
really
create
an
environment
that
helps
the
other
okay.
D
So
that
is
our
approach
in
doing
that
we
are
working
to
and
then
maybe
I
can
be
more
precision
process
in
that
we
are
thinking
in
into
that
direction.
Okay,
one
is
using
the
right
technology
open
technology.
We
want
to
really
reduce
the
barrier
to
the
adoption,
so
we
believe
that
the
open
technology
is
the
most
important
thing
to
do
that.
Okay
and
the
other
one
is
really
create
the
ecosystem
and
for
us
ecosystem
means
create
collaboration
in
different
player
of
the
more
than
the
supply
chain.
D
I
would
say
that
is
the
value
chain:
okay,
the
brings
for
us
the
product
to
the
end
user.
The
end
user
for
us
is
patient
and
also
doctor
also
clinic
okay.
So
we
believe
that
the
blockchain
it
becomes
something
that
a
sort
of
thing
is
as
a
I
would
say,
as
a
digital
highway,
which
everybody
can
have
the
ability
and
the
possibility
to
plug
it
in
very
easily
okay.
So
that
is
our
approach
in
which
they
can
share
data
in
a
and
information
in
a
trusted
way
and
also
in
a
con
very
controlled
way.
D
That
is
our
idea.
So,
in
order
to
do
that,
we
have
done
a
lot
of
project
internal
project
poc
at
the
moment,
and
then
we
have
started
collaborating
pharma
ledger
for
marriage
is
a
big
consortium
of
29
partner.
Okay,
it's
under
the
european
community
is
a
project
that
will
last
three
years:
okay
with
an
investment
public
and
private
of
21
million
okay,
and
we
are
really
leverage
the
use
of
the
blockchain
in
healthcare.
D
I
can
tell
you
that,
from
the
pharmaceutical
point
of
view,
this
is
very,
very
important,
because
there
are
something
like
12
pharmaceutical
company.
I
mean
12
of
the
first
15
pharmaceutical
comp
that
is
working
with
us
in
order
to
leverage
this
this
approach.
So
that's
is
this
this
this
our
idea.
In
theory.
Okay,
dda
is
really
create
a
transparency
increase.
The
speed
of
I
mean
transaction
that
me
helps
to
really
to
drive
efficiency
globally
around
the
world.
D
That
is
the
reason
why
we
are
working
with
the
as
a
pacific,
with
zoliga
and
with
the
other
partner,
but
most
important
thing.
I
will
say
that
the
open
software
after
and
everybody
need
to
really
have
the
the
right
approach
in
in
the
idea.
Okay
and
I'll
stop
here,
because
otherwise
I
can.
I
really
continue
to
talk,
but
I
don't
want
to
monetize
all
the
things.
Okay,.
A
So
it
sounds
like
right
now.
Most
of
the
the
projects
in
this
space
are
are
still
very
much
proofs
of
concept
and
and
maybe
there's
some
pilots.
What
would
any
of
the
three
of
you
consider,
perhaps
the
most
advanced
pilot
or
or
something
that's
starting
to
to
actually
be
in
production
right
now?
Is
there
are
there
any
kind
of
points
of
light
in
here?
What's
what's
the
one
where
there
seems
to
be
the
most
value
being
created,
the
most
promising
pilot
in
operation
right
now
using
distributed
ledger
technology.
D
If
I
say
something,
I
miss
the
word
that
we
are
doing
with
zurich,
so
we
can
really
create
a.
I
mean,
because
I
mean
everything
started
work
from
some
counterfeiting
problem
that
you
have
in
as
a
pacific
for
a
specific
vaccine.
Okay,
so
it
was
really
the
opportunity
to
think
and
starting
to
collaborate
with
other
person
on
the
on
the
field.
Okay,
so
I
would
say
that-
and
maybe
I
mean
really-
I
mean
the
daniel-
can
help
me
to
understand.
So
it's
a
sort
of
of
dialogue.
D
It
started
like
a
poc
involving
other
pharmaceutical
company.
Okay,
because
I
mean
the
idea
is
really
to
to
get
this
started,
and
now
we
have,
I
would
say
it's
almost
in
production,
okay,
or
at
least
we
think
that
as
a
modular
set,
okay,
which
the
blockchain
is,
is
really
a
baseline
in
which
you
can
build
capability.
One
of
the
capabilities
that
we
are
starting
to
we
have
already
done
was
the
the
anti-counterfeiting
tools
that
are
maybe
I'll
leave
them
into
to
talk
about
that
or
maybe
more
deeply
if
you
want
to.
D
But
on
top
of
that
now
we
are
really
building
integration
with
the
clinic
in
so
it's
the
the
layer
of
the
the
hyperledge
in
this
case,
but
I
mean
because
in
open
technology,
okay
is
helping
us
to
build
a
sort
of,
I
would
say
backbone
in
which
we
can
build,
build
the
capabilities,
okay
and
also
increase
the
ecosystem.
Okay,
and
so
we
have
also
the
I
mean
we
are
going
to
involve
also
the
the
the
local
government,
the
local
authorities,
and
so
we
believe
that
it's
become
big,
bigger
and
bigger.
Okay,.
A
Yeah,
let
me
turn
this
to
michael,
then,
to
talk
a
little
bit
more.
I
know
you're,
presenting
separately
on
in
depth
on
on
the
project
that
you're
doing
at
zulic
pharma.
But
can
you
give
us
a
sense
of
like
where
does
this
first
materialize
and
let
me
frame
it
this
way,
so
the
moderator
the
next
panel
is
michael
doe,
castillo
and
one
night
at
dinner
and
in
front
of
a
bunch
of
people.
A
He
turned
to
me
and
said:
show
me,
the
head
of
lettuce
show
me
the
head
of
lettuce
that
was
pulled
off
of
the
supermarket
shelf,
because
a
blockchain
somewhere
said
this
is
a
bad
head
of
lettuce.
Right
that
you
know
we
micro,
targeted
and
discovered,
was
on
the
same
pallet
as
these
other
bad
lettuce
and-
and
you
know-
and
we
discovered
that
like
that's-
that,
how
do
we
make
it
real?
A
How
do
we
know
when
it's
real
right,
when
when
will
we
see
like
the
first
package
of
drugs
that
were
pulled
off
the
shelf,
because
we
realized
thanks
to
the
use
of
distributed
ledger
technology
was
part
of
probably
the
fault
of
a
bad,
the
result
of
fraud,
or
something
like
that
like?
How
close
are
we
to
that
kind
of
proof?
Point
daniel.
That
was
question
to
you.
Sorry.
C
Apologies,
we
were
actually
there
now,
I
would
say
so.
We've
done
a
lot
of
work
with
with,
as
paolo
said,
with
msd.
We
have
live
solutions
in
in
some
of
the
markets
that
we're
in
certainly
in
in
hong
kong.
We
have
a
live
solution
there,
which
is
doing
what
we
hoped
it
would
do.
It's
showing
it's
showing
products,
it's
products
being
scanned,
we're
seeing
we're
getting
feedback,
we're
getting
indications
of
products
being
in
maybe
locations
that
they
they
weren't
actually
distributed
to.
C
C
I
think
kovit
is
obviously
accelerated,
because
there's
a
lot
of
a
lot
of
concern
that
we
will
see,
especially
in
asia,
counterfeit
vaccines
coming
into
the
supply
chain
at
various
points,
and
so
we
started
to
see
the
adoption
adoption
growing
that
in
that
area,
but
yeah
we
are.
We
are
not
in
a
situation
where
it's
a
it's
a
pilot.
C
A
B
Other
other
other
kinds
of
efforts
to
do
yes:
okay,
yeah,
so
we
definitely
did
the
connectors,
which
are
blockchain
agnostic.
We
did
some
pilots
and
and
the
tests,
so
we
are
ready
to
jump
in.
However,
to
go
back
to
the
previous
discussions,
I
mean
blockchain
as
such
is
important
platform
for
traceability
and
accountability.
B
Transparency,
but
that's
not
the
way
I
mean
we
need
the
applications
on
the
top
of
it.
So
these
are
our
standard
applications
that
we
used
even
before
with
the
connectors
which
are
transformed
to
to
to
join
the
the
blockchain,
and
we
here
we
are
back
to
the
fact
that
we
need
the
critical
mass.
We
need
everybody
who
are
participant
in
the
process
to
join
in
order
to
have
a
complete
solution.
B
I
mean
antares
itself
or
I
don't
know
somebody
else
itself
cannot
do
the
the
the
solution
or
provide
the
the
the
what
is
required
and
challenged
these
days,
for
example,
with
the
covid.
We
have
this
program
that
is
coming
coax,
which
is
a
good
example
now
whereby
we
we
need
to
get
together
to
offer
what
is
requested
and,
of
course,
we
have
throughout
rf
excel
solutions.
B
B
However,
this
new
initiative
with
farm
un
that
we
are
with
the
linux
foundation,
we
are
really
happy
to
to
to
come
together
with
with
companies
like
america
ibm
and
the
others
where
we
work
towards
the
the
proper
way
of
creating
a
critical
mass
and
basically,
what
I
think
it's
key
to
define
what
we
are
still
missing,
to
define.
Really
the
key
events
which
we
need
to
to
to
record
in
the
the
blockchain.
A
B
A
A
And
essentially,
you
know
in
our
speak
on
chain
versus
those
things
that
are
should
be
off
chain
just
you
know
you
want
a
time
stamp
for
them
or
some
way
to
prove
that
that's
true,
because
the
things
are
that
are
on
chain
are
easy
to
audit.
You
know.
Yes,
this
number
appeared
here
sat
here
and
then
was
you
know,
consumed
over
there
and
should
not
be
valid
again
right
if
it's
off
chain
it's
harder
to
get
that
integrity.
B
If
you
ask
me,
if
I'm
still
on
yeah,
I
think
it's
still
a
very
oh.
This
is
a
very
open
discussion.
Still
I
mean,
especially
in
pharma.
As
you
mentioned,
I
mean
pharmaceutical
company
is
very
regulated
environment.
I
mean
we
can
go
in
whole
topic
of
of
qa
data,
integrity
and
so
on.
So
it's
still
really
need.
I
I
I
mean
tech.
Always
it
and
technology
is
much
be
in
front
of
qa
and
standards
in
in
pharma
and
that
we
are
always.
I
mean
my
background.
Is
pharmaceutical.
It's
not
ids.
B
We
are
what
I've
learned
now
we
are
always
running
after
it
and,
of
course
we
have
a
regulator,
bodies
that
are
coming
up
with
the
standards,
but
we
will
all
have
to
come
together
to
work
towards
a
definition
of
the
key
events
and
the
standards
which
will
correspond
to
the
expectations
of
the
pharmaceutical
companies
and
of
ensuring
data
integrity
throughout
the
processes.
So
it's
really
hard
work
in
front
of
all
of
us.
I
mean
we
know
where
we
are
going.
We
know
how
to
get
there,
but
we
we
need
to
define.
A
Right
for
folks
who
might
not
be
familiar
in
this
domain,
one
of
the
foundational
laws
was
set
in
2013
by
something
called
in
the
united
states.
At
least
a
regulation
called
the
drug
supply
chain
security
act
in
2013,
which
stipulated
the
formation
of
a
whole
lot
of
reporting
mechanisms,
and
it
does
come
into
force.
It's
2022
right
that
it
comes
into
force.
I
think
where.
A
A
Right
where
it
will
require
reporting
and
traceability
down
to
the
individual
retail
package,
if
I
understand
this
correctly,
which
is
huge
and
tremendous,
let
me
ask
the
panel
and
and
maybe
I'll
look
at
paulo
a
little
bit
too
in
particular
on
this
question.
Do
you
think
it
takes
regulations
like
that
or
like
similar
ones
in
europe
that
have
emerged
to
to
to
get
this
industry
to
to
think
about
data
sharing
and
and
safety,
and
and
maybe
the
use
of
blockchain
technology?
A
D
Yeah,
as
lisa
was
saying,
I
mean
technology,
especially
in
the
indiana,
is,
is
really
most
advanced
if
you
think
of
what
we
can
really
achieve,
because
this
is
a
very
regulated
environment,
okay
and
if
you
think
of
this
type
of
event,
okay
legislation
event
also,
unfortunately
covered
event.
Okay,
unfortunately,
for
what
is
happening,
but
in
some
ways
is
a
sort
of
accelerating
thing
that
is
happening
is,
of
course,
something
that
can
help.
Okay,
as
lydia
was
saying,
I
mean
without
having
ecosystem,
okay,
especially
in
the
pharma.
We
cannot
do
anything.
D
D
Unfortunately,
I
went
like
like
calling
where
all
together
need
to
understand
how
they,
which
is
that
the
best
way
of
implementing
solution
to
be
open
and
the
the
people
okay
at
the
end
of
the
day,
so
I
believe
that
this
event
will
help
a
lot.
Okay,
think
of
the
effort
fmd
in
europe,
okay,
so
the
the
same
approach
of
anti-anti-anti-anti-contrafitti
in
europe,
okay-
and
that
really
was
a
really
push
of
the
serialization
of
the
product
that
had
the
is
one
of
the
most
important
without
every
serialization.
D
In
theory,
we
cannot
use
the
blockchain
because
we
are
building
the
digital
twin
of
the
product,
so
we
can
really
build
and
be
able,
tokenization
or
without
accommodation,
and
it's
something
that
we
need
to
really
understand.
It
is
a
link
to
the
transparency
and
the
fact
that
to
other
data
of
chain
of
chain
is
really
a
big
topic.
Okay,
that
need
to
be
understood,
and
then
I
believe
that
need
to
be
negotiated.
D
Also
with
the
with
the
the
authority
we
as
pharmaceutical
company,
I'm
talking
with
all
the
pharmaceutical
companies
working
together
with
farmer
ledger,
we
are
open
to
share
the
data.
Okay,
then
we
need
to
understand
that.
Maybe,
if
you
are
going
to
have
the
the
code
of
the
product
on
chain
and
every
can
look
at,
it-
can
also
create
an
opportunity
for
the
anti
for
the
contra
fitting
okay.
So
you
need
to
find
out
the
right
balance
in
order
to
make
this
happen.
D
Okay,
because
think
of
the
fact
that,
at
the
end
of
the
day,
the
patient
that
at
the
end
can
decide
to
share
data
with
the
pharmaceutical
company-
or
maybe
older
player,
knows
where
the
data
and
how
this
is
used,
and
you
can,
you
can
also
maybe
decide
over
really
stop
the
data
on
try
to
understand
and
give
specific
amino
approaches,
specific
data
to
be
used
for
specific
topic.
Okay,
so
it
becomes.
It
opens
a
completely
great
point
and
for
pharmaceutical
comp.
D
A
C
Yeah,
I
think
it's
it's
a
good
point.
You
know
in
in
asia.
There's
the
serialization
mandate
is
not
it's
not
there
yet,
so
it
does
make
being
able
to
have
a
blockchain
solution
that
that
little
bit
harder.
So
there's
nothing
like
you
have,
maybe
in
the
us
or
that's
coming
in
europe,
there's
only
a
career
where
they
actually
do
have
serialization
in
place.
D
Yeah,
if
I
may
have
add
something
on
top
of
that,
the
ecosystem
becomes
again
something
that
is
important.
Okay,
I
mean
in
our
approach
with
the
hong
kong
government.
Even
if
there
is
not
a
serialized
environment,
we
we
we
came
to
the
government
and
show
that
this
realization
would
be
good
okay,
so
we
have
one
product
in
the
market
that
is
serialized
the
one
that
this
guard
does
in
line
that
we
are
doing
the
pilot.
D
So
it's
becoming
also
more
and
more
important
for
officer
in
the
family
of
god
to
pharmaceutical
to
go
in
the
voluntary
serialization.
So
we
are
starting
to
involve
the
other.
I
mean
government
to
show
what
are
the
advantage
of
that
or
so
so
that
is,
that
the
power
of
the
ecosystem,
okay,
and
especially
when
you
are
doing
something
that
is
recognized
to
be,
I
mean
an
advantage
for
everyone:
okay,
like
open
software,
serialization
managing
the
data
in
the
right
way
having
the
data
privacy
in
the
right
way.
A
Okay,
what
do
any
of
you
consider
kind
of
some
remaining
outstanding
technical
hurdles
to
the
adoption
of
blockchain
technology
by
the
pharma
industry?
Are
there
specific
advancements
in
and
data
confidentiality
and
performance,
or
other
things
that
that
you
know
seem
essential
to
solve
before
we
can?
We
can
apply
it
to
the
scale
of
the
challenge.
B
A
D
Okay,
I
would
say
that
scalability
for
us
is
still
a
question
mark,
not
because
we
don't
know
that,
but
we
haven't
yet
tried.
Okay,
so
in
theory
on
the
paper
everything
is
is
is
okay,
so
we
need
really
to
try
and
understand
scalability
and
also
to
to
I
mean
for
at
the
moment
we
are
looking
at
the
private
blockchain
okay
at
the
moment,
especially
in
this
sort
of
type
of
transaction,
where
they
are
transaction
intensive.
D
Okay,
so
we
are
thinking
of
trying
to
understand
what
is
and
also
the
effect
of
having
the
analytics
on
top
of
the
blockchain
becomes
something
that
is
very
important.
I
mean
transaction
without
analytics.
We
have
the
ability
to
to
understand
what
is
the
data
is
nothing
okay,
so
it's
it's!
It's
really
the
thing
so
the
other
thing
in
which
we
nearly
would
then
understand
the
balance
between
off
chain
on
chain
and
the
ability
to
have
specific
to
analytic
tools
that
can
be
shared
with
the
security.
Okay.
D
B
So
if
we
don't
come
together
and
define
all
these
things
that
we
will
have
a
lot
of
technical
hurdles
which
will
be
actually
structural
hurdles
in
my
in
my
point,
we
really
need
to
concentrate
on
that
one
first
and
then
the
other
one,
because
technology
is
always
advanced,
I
mean
technology
will
sort
it
out
once
we
have
a
form
and
we
have
a
proper
definition
of
of
what
exactly
we
are.
We
are
doing
to
the
to
the
points.
A
That's
great
well,
all
three
of
you
are
pioneers
in
this
space.
I
I
think,
we're
all
very
lucky
to
have
you
on
the
case
figuring
out
how
to
use
blockchain
technology
to
help
harden
and
and
update
the
supply
chain,
for
what
could
not
be
one
of
the
most
critical
pieces
of
both
fighting
the
pandemic,
but
also
helping
us
lead
to
a
safer
society.
So
I
want
to
thank
all
three
of
you
I
and
yeah.
This
is
a
really
educational
and
fun
fun
conversation.